Literature DB >> 3864001

Methotrexate-vindesine association in leukemia: pharmacokinetic study.

N Tubiana, N Lena, J Barbet, A M Imbert, C Lejeune, D Maraninchi, D Sainty, G Sebahoun, J A Gastaut, J P Cano.   

Abstract

Methotrexate (MTX) and vindesine (VDS) have both been found effective in the treatment of acute leukemia. With regard to their pharmacological effects at the cellular level they can reportedly interact. Administration of MTX at high dose levels has been suggested as both a curative and preventive treatment of blastic meningitis. The purpose of this work was to determine whether an injection of VDS leads to any change in MTX clearance and uptake in the cerebrospinal fluid (CSF). The plasma pharmacokinetic and CSF influx of MTX and VDS were assayed after high dose systemic MTX with an intravenous bolus of VDS administered in the treatment of acute lymphoblastic leukemia. The MTX concentration was determined by enzymatic assay and VDS by radio immunoassay. No interrelation between these drugs was found. MTX levels in the CSF were sufficient for therapeutic effectiveness but were not affected by intravenous VDS. Detectable amounts of VDS were observed in the CSF but were not altered by MTX.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3864001     DOI: 10.1007/bf02934855

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  9 in total

Review 1.  TECHNIQUES FOR STUDY OF RESISTANCE TO FOLIC ACID ANTAGONISTS.

Authors:  J R BERTINO; G A FISCHER
Journal:  Methods Med Res       Date:  1964

2.  Characteristics of the vincristine-induced augmentation of methotrexate uptake in Ehrlich ascites tumor cells.

Authors:  M J Fyfe; I D Goldman
Journal:  J Biol Chem       Date:  1973-07-25       Impact factor: 5.157

3.  Comparison of three methods of central-nervous-system prophylaxis in childhood acute lymphoblastic leukaemia.

Authors:  D M Green; A I Freeman; H N Sather; S E Sallan; M E Nesbit; J R Cassady; L F Sinks; D Hammond; E Frei
Journal:  Lancet       Date:  1980-06-28       Impact factor: 79.321

4.  Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas.

Authors:  M Bayssas; J Gouveia; P Ribaud; M Musset; F de Vassal; J L Pico; L de Luca; J L Misset; D Machover; D Belpomme; L Schwarzenberg; C Jasmin; M Hayat; G Mathé
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

5.  Exchangeable intracellular methotrexate levels in the presence and absence of vincristine at extracellular drug concentrations relevant to those achieved in high-dose methotrexate-folinic acid "rescue" protocols.

Authors:  I D Goldman; V Gupta; J C White; S Loftfield
Journal:  Cancer Res       Date:  1976-01       Impact factor: 12.701

6.  Vincristine effect on methotrexate cerebrospinal fluid concentration.

Authors:  F Tejada; C G Zubrod
Journal:  Cancer Treat Rep       Date:  1979-01

7.  Methotrexate-vindesine association in the treatment of head and neck cancer influence of vindesine on methotrexate's pharmacokinetic behavior.

Authors:  N Lena; A M Imbert; T Pignon; R Favre; G Meyer; J P Cano; Y Carcassonne
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia.

Authors:  P L Chello; F M Sirotnak
Journal:  Cancer Treat Rep       Date:  1981 Nov-Dec

9.  High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach.

Authors:  S Monjanel; J P Rigault; J P Cano; Y Carcassonne; R Favre
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

  9 in total
  3 in total

Review 1.  Pharmacokinetic considerations in the treatment of CNS tumours.

Authors:  Susannah Motl; Yanli Zhuang; Christopher M Waters; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3.

Authors:  Chenrong Huang; Fan Xia; Ling Xue; Linsheng Liu; Yicong Bian; Zhengming Jin; Liyan Miao
Journal:  Cancer Chemother Pharmacol       Date:  2019-11-05       Impact factor: 3.333

Review 3.  Drug interactions at the blood-brain barrier: fact or fantasy?

Authors:  Sara Eyal; Peng Hsiao; Jashvant D Unadkat
Journal:  Pharmacol Ther       Date:  2009-04-22       Impact factor: 13.400

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.